Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

The promising feeder-free allogenic NK cell therapy: Clinical outcomes of GIC-102 monotherapy (GIC-102101) and synergistic potential with GI-101 (CD80-IgG4 Fc-IL2v) in advanced solid tumors and hematologic malignancies.

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSoo Hyun LeeJHJunshik HongHCHyungwoo Cho

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lee et al. (2024) studied this question.

synapsesocial.com/papers/68e67054b6db6435875fa896https://doi.org/10.1200/jco.2024.42.16_suppl.e14526
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation.2024 · 3 citations
  2. 2Abstract CT242: Phase 2b study of alloHSCT patients receiving RGI-2001, an NKT cell activator, demonstrates safety and protection from acute GVHD, correlating with increased NKT cell number in patient blood2024
  3. 3Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies2025 · 1 citations
  4. 4Phase 1 study of GT101 as an autologous tumor infiltrating lymphocyte (TIL) therapy in advanced solid tumors.2024 · 2 citations
  5. 5Abstract 7758: Prediction of pharmacokinetics and pharmacodynamics profile for a fixed dosing and body weight-based dosing of GI-102 based on cell-level pharmacodynamics-mediated drug disposition model in patients with advanced or metastatic solid tumors2026